Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab.

Cancer Cell Int · 2014 · PMC4007516 · PMID 24624997

Europe PMC DOI

hedged sentences

0.0110

closest p · 0.2× alpha

0.2270

boldest claim

The sentences

showed a trendp = 0.011actually significant

Results We did not observe obvious correlation between patients’ disease features and STAT3 polymorphisms, but patients with homozygous genotypes at rs2293162 showed a trend of higher CR rate than those with the heterozygous genotype, especially in non-GCB subgroup ( p = 0.011).

also in 53,322 other papers

did not reach statistical significancep = 0.227not close (p > 0.1)

Patients with homozygous genotypes had a median PFS of 909 days (range, 60–1851) versus 920 days (range, 78–2591) for the heterozygous CG genotype patients, but the differences between these two groups did not reach statistical significance ( p = 0.227).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.